logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: COMBI-AD follow-up confirms dabrafenib/trametinib benefit

Longer-term follow-up confirms RFS advantage observed in primary analysis.